Catalyst Pharmaceutical Partners shares owned by Credit Suisse
Quarter-by-quarter ownership of Catalyst Pharmaceutical Partners (CPRX) shares owned by Credit Suisse
from 13F filings
Historical chart of Credit Suisse investment in Catalyst Pharmaceutical Partners
Tip: Access up to 7 years of quarterly data
All positions including Catalyst Pharmaceutical Partners held by Credit Suisse consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelQuarterly reported holdings in Catalyst Pharmaceutical Partners by Credit Suisse
Quarter filed | Position value | Share count | Share price at filing |
---|---|---|---|
2024-03-31 | $1.9M | 117k | 15.94 |
2023-12-31 | $1.8M | 109k | 16.81 |
2023-09-30 | $1.3M | 108k | 11.69 |
2023-06-30 | $1.9M | 142k | 13.44 |
2023-03-31 | $1.4M | 86k | 16.58 |
2022-12-31 | $1.5M | 83k | 18.60 |
2022-09-30 | $1.0M | 81k | 12.83 |
2022-06-30 | $485k | 69k | 6.99 |
2022-03-31 | $600k | 72k | 8.31 |
2021-12-31 | $502k | 74k | 6.77 |
2021-09-30 | $368k | 71k | 5.18 |
2021-06-30 | $364k | 64k | 5.68 |
2021-03-31 | $651k | 87k | 7.52 |
2020-12-31 | $636k | 194k | 3.29 |
2020-09-30 | $911k | 306k | 2.98 |
2020-06-30 | $1.4M | 296k | 4.62 |
2020-03-31 | $1.2M | 320k | 3.83 |
2019-12-31 | $2.1M | 562k | 3.74 |
2019-09-30 | $522k | 56k | 9.26 |
2019-06-30 | $183k | 48k | 3.85 |
2019-03-31 | $138k | 21k | 6.45 |
2018-12-31 | $29k | 15k | 1.93 |
2018-06-30 | $79k | 25k | 3.17 |
2018-03-31 | $77k | 31k | 2.47 |
2017-12-31 | $84k | 22k | 3.90 |
2017-09-30 | $120k | 48k | 2.51 |
2017-06-30 | $38k | 14k | 2.70 |
2017-03-31 | $31k | 16k | 1.94 |
2016-12-31 | $17k | 16k | 1.06 |
2016-09-30 | $157k | 144k | 1.09 |
2016-06-30 | $302k | 425k | 0.71 |
2016-03-31 | $116k | 98k | 1.18 |
2015-12-31 | $135k | 56k | 2.40 |
2015-09-30 | $101k | 35k | 2.91 |
2015-06-30 | $164k | 39k | 4.20 |
2015-03-31 | $694k | 160k | 4.33 |
2014-12-31 | $193k | 65k | 2.97 |
2014-09-30 | $151k | 45k | 3.33 |
2013-06-30 | $12k | 14k | 0.86 |
Top funds holding Catalyst Pharmaceutical Partners
View all funds holding Catalyst Pharmaceutical Partners